skip to main content
Language:
Show Results with:
Refined by: collection: MEDLINE/PubMed (NLM) remove collection: Scopus (Elsevier) remove journal title: Lancet remove author: Komajda, Michel remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Material Type:
Article 		Add to My workspace

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Lancet (London, England), June 20, 2009, Vol.373(9681), pp.2125-2135 [Peer Reviewed Journal]

No full-text

View all versions

All text is © British Library Board and is available under a Creative Commons Attribution Licence, except where otherwise stated.

P3

Searching Remote Databases, Please Wait